Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

por Bok, Karin, Sitar, Sandra, Graham, Barney S., Mascola, John R.
Publicado 2021

Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission

por Friedman-Klabanoff, DeAnna J, Fitzpatrick, Meagan C, Deming, Meagan E, Agrawal, Vaidehi, Sitar, Sandra, Schaafsma, Torin, Brown, Elizabeth, Neuzil, Kathleen M, Barnabas, Ruanne V, Laufer, Miriam K
Publicado 2022

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

por Sarwar, Uzma N., Costner, Pamela, Enama, Mary E., Berkowitz, Nina, Hu, Zonghui, Hendel, Cynthia S., Sitar, Sandra, Plummer, Sarah, Mulangu, Sabue, Bailer, Robert T., Koup, Richard A., Mascola, John R., Nabel, Gary J., Sullivan, Nancy J., Graham, Barney S., Ledgerwood, Julie E.
Publicado 2015

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults

por Crank, Michelle C., Gordon, Ingelise J., Yamshchikov, Galina V., Sitar, Sandra, Hu, Zonghui, Enama, Mary E., Holman, LaSonji A., Bailer, Robert T., Pearce, Melissa B., Koup, Richard A., Mascola, John R., Nabel, Gary J., Tumpey, Terrence M., Schwartz, Richard M., Graham, Barney S., Ledgerwood, Julie E.
Publicado 2015

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

por Gaudinski, Martin R., Coates, Emily E., Houser, Katherine V., Chen, Grace L., Yamshchikov, Galina, Saunders, Jamie G., Holman, LaSonji A., Gordon, Ingelise, Plummer, Sarah, Hendel, Cynthia S., Conan-Cibotti, Michelle, Lorenzo, Margarita Gomez, Sitar, Sandra, Carlton, Kevin, Laurencot, Carolyn, Bailer, Robert T., Narpala, Sandeep, McDermott, Adrian B., Namboodiri, Aryan M., Pandey, Janardan P., Schwartz, Richard M., Hu, Zonghui, Koup, Richard A., Capparelli, Edmund, Graham, Barney S., Mascola, John R., Ledgerwood, Julie E.
Publicado 2018

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

por Gaudinski, Martin R, Houser, Katherine V, Morabito, Kaitlyn M, Hu, Zonghui, Yamshchikov, Galina, Rothwell, Ro Shauna, Berkowitz, Nina, Mendoza, Floreliz, Saunders, Jamie G, Novik, Laura, Hendel, Cynthia S, Holman, LaSonji A, Gordon, Ingelise J, Cox, Josephine H, Edupuganti, Srilatha, McArthur, Monica A, Rouphael, Nadine G, Lyke, Kirsten E, Cummings, Ginny E, Sitar, Sandra, Bailer, Robert T, Foreman, Bryant M, Burgomaster, Katherine, Pelc, Rebecca S, Gordon, David N, DeMaso, Christina R, Dowd, Kimberly A, Laurencot, Carolyn, Schwartz, Richard M, Mascola, John R, Graham, Barney S, Pierson, Theodore C, Ledgerwood, Julie E, Chen, Grace L
Publicado 2018